Bayer Edging Closer to Litigation Resolution -- Market Talk

Dow Jones03-16 22:28

1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 16, 2026 10:28 ET (14:28 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619461137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619461137","market":"fut","top_or_hot":-1,"title":"Bayer Edging Closer to Litigation Resolution -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 10:28 ET (14:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Edging Closer to Litigation Resolution -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Edging Closer to Litigation Resolution -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-16 22:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 10:28 ET (14:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619461137","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619461137","pubTimestamp":1773671280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4007":"制药"},"translate_title":"拜耳距离诉讼解决方案越来越近——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 10:28 ET (14:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619461137","isCrawlerRequest":true}